US drug regulator rejects Atara Biotherapeuticsâ rare cancer therapy
Atara Biotherapeuticsâ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Drugs
Health
Pharma